Trial · NCT01465659
Adverse events672
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 672
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hearing impaired | Ear and labyrinth disorders | Cohort 1 - Temozolomide 150 mg/m2 and Pazopanib 400 mg | 1 | 7 | |
| other | Hearing impaired | Ear and labyrinth disorders | Cohort -1 -Temozolomide 100 mg/m2 and Pazopanib 400 mg | 0 | 5 | |
| other | Hearing impaired | Ear and labyrinth disorders | Cohort -2 - Temozolomide 75 mg/m2 and Pazopanib 400 mg | 0 | 6 | |
| other | Hearing impaired | Ear and labyrinth disorders | Phase II -Temozolomide 75 mg/m2 and Pazopanib 400 mg | 1 | 17 | |
| other | Hemoglobin (anemia) | Blood and lymphatic system disorders | Cohort 1 - Temozolomide 150 mg/m2 and Pazopanib 400 mg | 6 | 7 | |
| other | Hemoglobin (anemia) | Blood and lymphatic system disorders | Cohort -1 -Temozolomide 100 mg/m2 and Pazopanib 400 mg | 4 | 5 | |
| other | Hemoglobin (anemia) | Blood and lymphatic system disorders | Cohort -2 - Temozolomide 75 mg/m2 and Pazopanib 400 mg | 3 | 6 | |
| other | Hemoglobin (anemia) | Blood and lymphatic system disorders | Phase II -Temozolomide 75 mg/m2 and Pazopanib 400 mg | 6 | 17 | |
| other | Petechiae | Blood and lymphatic system disorders | Cohort 1 - Temozolomide 150 mg/m2 and Pazopanib 400 mg | 1 | 7 | |
| other | Petechiae | Blood and lymphatic system disorders | Cohort -1 -Temozolomide 100 mg/m2 and Pazopanib 400 mg | 0 | 5 | |
| other | Petechiae | Blood and lymphatic system disorders | Cohort -2 - Temozolomide 75 mg/m2 and Pazopanib 400 mg | 0 | 6 | |
| other | Petechiae | Blood and lymphatic system disorders | Phase II -Temozolomide 75 mg/m2 and Pazopanib 400 mg | 0 | 17 | |
| other | Red blood cells decreased | Blood and lymphatic system disorders | Cohort 1 - Temozolomide 150 mg/m2 and Pazopanib 400 mg | 0 | 7 | |
| other | Red blood cells decreased | Blood and lymphatic system disorders | Cohort -1 -Temozolomide 100 mg/m2 and Pazopanib 400 mg | 0 | 5 | |
| other | Red blood cells decreased | Blood and lymphatic system disorders | Cohort -2 - Temozolomide 75 mg/m2 and Pazopanib 400 mg | 1 | 6 | |
| other | Red blood cells decreased | Blood and lymphatic system disorders | Phase II -Temozolomide 75 mg/m2 and Pazopanib 400 mg | 0 | 17 | |
| other | Sinus bradycardia | Cardiac disorders | Cohort 1 - Temozolomide 150 mg/m2 and Pazopanib 400 mg | 1 | 7 | |
| other | Sinus bradycardia | Cardiac disorders | Cohort -1 -Temozolomide 100 mg/m2 and Pazopanib 400 mg | 0 | 5 | |
| other | Sinus bradycardia | Cardiac disorders | Cohort -2 - Temozolomide 75 mg/m2 and Pazopanib 400 mg | 0 | 6 | |
| other | Sinus bradycardia | Cardiac disorders | Phase II -Temozolomide 75 mg/m2 and Pazopanib 400 mg | 0 | 17 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01465659/events